Delcath Systems (NASDAQ:DCTH) Upgraded at StockNews.com

StockNews.com upgraded shares of Delcath Systems (NASDAQ:DCTH) from a sell rating to a hold rating in a research note issued to investors on Friday.

A number of other research analysts have also issued reports on DCTH. Craig Hallum started coverage on Delcath Systems in a report on Friday, June 28th. They issued a “buy” rating and a $18.00 target price for the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $21.00 price target on shares of Delcath Systems in a report on Friday, October 18th. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Delcath Systems in a report on Friday, October 18th. Finally, Stephens reaffirmed a “buy” rating on shares of Delcath Systems in a report on Friday, October 18th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Delcath Systems has an average rating of “Moderate Buy” and a consensus price target of $21.50.

Delcath Systems Trading Down 1.7 %

NASDAQ:DCTH opened at $10.50 on Friday. The firm has a market cap of $291.75 million, a PE ratio of -3.96 and a beta of 0.78. The stock has a fifty day moving average price of $9.52 and a 200 day moving average price of $8.00. Delcath Systems has a 12-month low of $2.25 and a 12-month high of $11.74.

Delcath Systems (NASDAQ:DCTH) last released its earnings results on Monday, August 5th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12). The company had revenue of $7.77 million during the quarter, compared to analysts’ expectations of $5.00 million. Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. During the same quarter last year, the business posted ($0.58) earnings per share. Equities analysts forecast that Delcath Systems will post -1.67 EPS for the current year.

Institutional Trading of Delcath Systems

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Rosalind Advisors Inc. increased its position in shares of Delcath Systems by 155.1% during the second quarter. Rosalind Advisors Inc. now owns 2,650,389 shares of the company’s stock worth $22,184,000 after purchasing an additional 1,611,561 shares in the last quarter. AIGH Capital Management LLC increased its position in shares of Delcath Systems by 1.7% during the second quarter. AIGH Capital Management LLC now owns 2,399,792 shares of the company’s stock worth $20,086,000 after purchasing an additional 40,064 shares in the last quarter. BVF Inc. IL increased its position in Delcath Systems by 23.1% in the 1st quarter. BVF Inc. IL now owns 1,202,067 shares of the company’s stock valued at $5,734,000 after acquiring an additional 225,918 shares during the period. Vanguard Group Inc. increased its position in Delcath Systems by 31.0% in the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after acquiring an additional 161,678 shares during the period. Finally, Shellback Capital LP acquired a new position in Delcath Systems in the 2nd quarter valued at about $1,353,000. Institutional investors and hedge funds own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.